http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Carbenoxolone sodium 이 흰쥐의 의액 및 위궤양 형성에 미치는 영향에 관한 실험적 연구
박실무,김종숙,이기환,고대진 대한소화기학회 1977 대한소화기학회지 Vol.9 No.2
This experimental study on the effects of carbenoxolone sodium(Bigastrone, Berk), which is, synthesized from glycyrrhetinic acid and di-sodium salt, was performed with the use of ulcerinduced Shay rats. The following results were obtained: (1) The ulcer index revealed the decrease in the carbenoxolone sodium group as compared with the control group indicating 21;8. (2) The amount of gastric secretion revealed rather increase in the carbenoxolone sodium group as compared with the control group indicating 11.1±1.6ml. (3) In determination of total acidity arid free Hcl of gastric juice, there could be demonstrated the marked decrease in the carbenoxolone sodium 200mg/kg administration as compared with the control group indicating 70.6±15.6mEq/L and 38.0±14.2mEq/L. (4) In determination of total protein and mucoprotein, there could be seen the marked increase in the gastric juice of carbenoxolone sodium 200mg/kg group in comparision with 707.7±117.4mg/dl of total protein and 230.6±47.5mg/dl of mucoprotein in control group. (5) In result of electrophoresis on gastric juice of the rats, there could be demonstrated the three more fractions in comparison with serum electrophoresis. In fractionation of gastric juice electrophoresis of rats, we could be seen the decrease in the 1,2 and 3 fraction, but the marked. Increase in the 4 and 5 fraction indicating 14.6% and 17.1% and there could be demonstrated the striking P.A.S. staining. At last, there could be observed the marked effects on gastric ulcer suppression by carbenox- olone sodium administration as compared with the control group.
Rabeprazole을 포함한 3제요법의 헬리코박터 파이로리 제균 효과와 CYP2C19 유전자형의 영향
박상종,이상배,류지곤,이진광,김회진,배진수,정현승,박실무 대한소화기학회 2003 대한소화기학회지 Vol.42 No.6
Genetic polymorphism of cytochrome P450 CYP2C19 influences the efficacy of proton pump inhibitor (PPI) in Helicobacter pylori (H. pylori) eradication therapy. We investigated the difference in the cure rates of H. pylori infection by triple (rabeprazole plus amoxacillin and clarithromycin) therapy in relation to CYP2C19 genotype status. Methods: One hundred and sixteen H. pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b.i.d., 1,000 mg amoxacillin b.i.d. and 500 mg of clarithromycin b.i.d. for one week. The genotype of CYP2C19 was determined by a PCR-restriction fragment length polymorphism method. Results: According to the univariate analysis, heterozygous extensive metabolizers (hetero EMs) and poor metabolizers (PMs) showed the highest (87.0%) and the lowest (80.0%) eradication rates, respectively. The difference in the therapeutic efficacy of rabeprazole among the different CYP2C19 genotypes was insignificant. With regard to gender, age and smoking history in relation to eradication rate, a statistical significance was noted only with age with odds ratio of 1.063 and p-value of 0.0202. Conclusions: In the eradication therapy of H. pylori, no statistically significant difference in therapeutic efficacy of rabeprazole was found among different CYP2C19 genotypes.